BioEcho Life Sciences announces FDA listing of its EchoLUTION Viral RNA/DNA Kit for nucleic acid extraction

“BioEcho is proud to provide a product that enables convenient extraction of viral RNA and DNA. We believe these products, which are FDA-listed in the US, will have a significant impact on improving efficiency for diagnostics laboratories and ultimately decreasing response times for patients”, underlines Lydia Willing, General Manager at BioEcho Life Sciences, Inc.

One of the key benefits of the EchoLUTION Viral RNA/DNA Kit is its technology, which is based on a tailored lysis followed by nucleic acid purification in a single centrifugation step. For respiratory viruses, no incubation is needed, for stool samples it is as short as 10 minutes. This means that the purified viral RNA or DNA from 96 samples is ready to use within 20–30 minutes depending on the sample type (swabs in medium, dry swabs, or stool samples). The kit is available in different formats (48-and 96-well plates) to adapt laboratory throughput to demands. The product is compatible with a variety of downstream applications such as qPCR.